Table V.
Summary of previous studies.
| Regimen | N | mPFS (months) | mOS (months) | AE-ILD | FN | (Refs.) |
|---|---|---|---|---|---|---|
| CBDCA+PTX | 15 | 2.5 | 7.0 | 4/15 | 0/15 | (20) |
| CBDCA+PTX | 16 | 5.3 | 10.6 | 1/16 | 1/16 | (19) |
| CBDCA+PTX | 11 | 4.4 | 9.7 | 0/11 | 0/11 | (21) |
| CBDCA+PTX+BEV | 10 | 5.3 | 16.1 | 1/10 | 0/10 | (21) |
| CBDCA+PTX+BEV | 5 | ND | ND | 2/5 | ND | (18) |
| CBDCA+PTX+BEV | 25 | 7.2 | 8.5 | 3/25 | 5/25 | (22) |
| CBDCA+S-1 | 21 | 4.2 | 9.7 | 2/21 | 0/21 | (23) |
| CBDCA+nab-PTX | 9 | 5.8 | 11.8 | 0/9 | 3/9 | Present |
ND, not described; mPFS, median progression-free survival; mOS, median overall survival; AE-ILD, acute exacerbation-interstitial lung disease; FN, febrile neutropenia; CBDCA, carboplatin; PTX, paclitaxel; BEV, bevacizumab; nab-PTX, albumin-bound paclitaxel.